Beam Therapeutics Inc.

BEAMNASDAQ

Market cap2.6B USDAs of Sep 22, 2026

Healthcare· Biotechnology· US

$25.26

Session change unavailable

Market closed · NASDAQ

Status checked Oct 24, 2026, 7:48 PM · America/New_York

Observed Sep 21, 2026, 8:00 PM UTC · Last available price

Beam Therapeutics Inc. (BEAM)

Loading market observation…

Beam Therapeutics Inc. (BEAM) stock forecast and scoring

Review the dated model forecast and five-factor Scorecard for BEAM. Each has its own availability and reference date; a score is a relative comparison, not a price prediction.

12M forecast summary

Target date · Sep 21, 2027

Lower Estimate (P10)

$12.73

-49.6%

Median Estimate (P50)

$30.25

+19.8% from starting price

Upper Estimate (P90)

$62.50

+147.4%

Median Estimate: $30.25
Starting price: $25.26
Change from starting price: +19.8%
Target date: Sep 21, 2027
Data through: Sep 21, 2026

The estimate uses its dated starting price. It does not predict returns from today’s quote.

View forecast details, dates and available ranges

Stock scorecard

Loading research…

Company Overview

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Similar Stocks

Research snapshot

Loading research…

Beam Therapeutics Inc. research

Loading research…

Model estimates are informational, not investment advice. They are uncertain, may be wrong, and do not guarantee future prices.

Company Overview

Similar Stocks

Explore related companies in our coverage. Open a stock for its full forecast and Scorecard.

Cogent Biosciences, Inc.

COGT

Same industryBiotechnology

Latest observed price

$32.00

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$38.23

+19.5%

From $32.00 starting price

Target Sep 21, 2027

Overall Score

Unavailable

Forecast basis Sep 21, 2026

Score date —

View stock

ImmunityBio, Inc.

IBRX

Same industryBiotechnology

Latest observed price

$8.45

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$9.97

+18.0%

From $8.45 starting price

Target Sep 21, 2027

Overall Score

Unavailable

Forecast basis Sep 21, 2026

Score date —

View stock

Recursion Pharmaceuticals, Inc.

RXRX

Same industryBiotechnology

Latest observed price

$3.97

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$4.65

+17.3%

From $3.97 starting price

Target Sep 21, 2027

Overall Score

Unavailable

Forecast basis Sep 21, 2026

Score date —

View stock

Vertex Pharmaceuticals Incorporated

VRTX

Same industryBiotechnology

Latest observed price

$510.72

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$546.06

+6.9%

From $510.72 starting price

Target Sep 21, 2027

Overall Score

Strong

Forecast basis Sep 21, 2026

Score date Sep 22, 2026

View stock

12-month forecasts show model median estimates (P50), with changes from each forecast’s starting price. Headline scores describe dated company characteristics; they do not predict future performance.

Beam Therapeutics Inc. (BEAM)

Beam Therapeutics Inc. (BEAM) stock forecast and scoring

12M forecast summary

Stock scorecard

Company Overview

Similar Stocks

Research snapshot

Beam Therapeutics Inc. research

Beam Therapeutics Inc. (BEAM) stock forecast and scoring

12M forecast summary

Scoring · Beam Therapeutics Inc. (BEAM) stock scorecard

Scoring Breakdown

Growth

Value

Quality

Safety

Momentum

Cash Generation & Balance Strength

Stock scorecard

Company Overview